Markus Reiser

2.5k citations

45 papers · 1.9k indexed · h-index 18

Impact in

Hepatology top 0.5%
- Hepatitis C virus research
Virology top 5%
- HIV Research and Treatment

Papers in ⓘ

Hepatology 26
- Hepatitis C virus research 20
- Hepatocellular Carcinoma Treatment and Prognosis 4
Epidemiology 15
- Liver Disease Diagnosis and Treatment 11
- Hepatitis B Virus Studies 9

Co-authors: Wolff Schmiegel (11 shared papers)Georg M. Lauer (4 shared papers)Paul Klenerman (5 shared papers)Heiner Wedemeyer (4 shared papers)Gerhard Nehmiz (5 shared papers)Michaela Lucas (3 shared papers)Kei Ouchi (3 shared papers)Raymond T. Chung (3 shared papers)
Journals: Hepatology (4 papers)Journal of Virology (4 papers)Gastroenterology (4 papers)Journal of Hepatology (3 papers)RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren (3 papers)
Partner nations: Germany United States United Kingdom

In The Last Decade

Markus Reiser

43 papers receiving 1.8k citations

Peers

Countries citing papers authored by Markus Reiser

Since Specialization

Citations

This map shows the geographic impact of Markus Reiser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Reiser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Reiser more than expected).

Fields of papers citing papers by Markus Reiser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Reiser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Reiser. The network helps show where Markus Reiser may publish in the future.

Co-authors

The 25 scholars most cited alongside Markus Reiser, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Markus Reiser Line = papers co-authored together Markus Reiser links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection Gastroenterology ·Georg M. Lauer, Eleanor Barnes, Michaela Lucas, Jörg Timm, Kei Ouchi, Arthur Y. Kim, Cheryl L. Day, Gregory K. Robbins, Deborah Casson, Markus Reiser, Geoffrey Dusheiko, Todd M. Allen, Raymond T. Chung, Bruce D. Walker, Paul Klenerman	2004	241
2	Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients Gastroenterology ·Holger Hinrichsen, Yves Benhamou, Heiner Wedemeyer, Markus Reiser, Roel Sentjens, José Luís Calleja, Xavier Forns, Andreas Erhardt, Jens Crönlein, Ricardo L. Chaves, Chan‐Loi Yong, Gerhard Nehmiz, Gerhard Steinmann	2004	233
3	Feasibility and Diagnostic Utility of Video Capsule Endoscopy for the Detection of Small Bowel Polyps in Patients with Hereditary Polyposis Syndromes The American Journal of Gastroenterology ·Karsten Schulmann, Stephan Hollerbach, Katja Kraus, Jörg Willert, Tilman Vogel, Gabriela Möslein, Christian Pox, Markus Reiser, Anke Reinacher‐Schick, Wolff Schmiegel	2005	171
4	Comprehensive Analysis of CD8⁺-T-Cell Responses against Hepatitis C Virus Reveals Multiple Unpredicted Specificities Journal of Virology ·Georg M. Lauer, Kei Ouchi, Raymond T. Chung, Tam Nguyen, Cheryl L. Day, Deborah R. Purkis, Markus Reiser, Arthur Y. Kim, Michaela Lucas, Paul Klenerman, Bruce D. Walker	2002	162
5	Detection of novel biomarkers of liver cirrhosis by proteomic analysis # Hepatology ·Christian Mölleken, Barbara Sitek, Corinna Henkel, Gereon Poschmann, Bence Sipos, Sebastian Wiese, Bettina Warscheid, Christoph E. Broelsch, Markus Reiser, Scott L. Friedman, Ida Tornøe, Anders Schlosser, Günter Klöppel, Wolff Schmiegel, Helmut E. Meyer, Uffe Holmskov, Kai Stühler	2008	123
6	Antiviral efficacy of NS3‐serine protease inhibitor BILN‐2061 in patients with chronic genotype 2 and 3 hepatitis C†‡ Hepatology ·Markus Reiser, Holger Hinrichsen, Yves Benhamou, H. W. Reesink, Heiner Wedemeyer, C. Avendaño, N. Riba, Chan‐Loi Yong, Gerhard Nehmiz, Gerhard Steinmann	2005	121
7	Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection Journal of Hepatology ·Markus Reiser, Constantine G. Marousis, David R. Nelson, Georg M. Lauer, Regino P. González‐Peralta, Gary L. Davis, Johnson Y.N. Lau	1997	92
8	Full-Breadth Analysis of CD8 ⁺ T-Cell Responses in Acute Hepatitis C Virus Infection and Early Therapy Journal of Virology ·Georg M. Lauer, Michaela Lucas, Jörg Timm, Kei Ouchi, Arthur Y. Kim, Cheryl L. Day, Julian Schulze zur Wiesch, Gláucia Paranhos‐Baccalà, Isabelle Sheridan, Deborah Casson, Markus Reiser, Rajesh T. Gandhi, Bin Li, Todd M. Allen, Raymond T. Chung, Paul Klenerman, Bruce D. Walker	2005	85
9	Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsy of Liver Lesions: Histological and Cytological Assessment Endoscopy ·Stefan Hollerbach, J Willert, T Topalidis, Markus Reiser, Wolff Schmiegel	2003	77
10	Mesalazine Changes Apoptosis and Proliferation in Normal Mucosa of Patients with Sporadic Polyps of the Large Bowel Endoscopy ·A. Reinacher-Schick, F. Seidensticker, S. Petrasch, Markus Reiser, S. Philippou, Dirk Theegarten, G Freitag, Wolff Schmiegel	2000	66
11	Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study Journal of Hepatology ·Markus Cornberg, Johannes Hadem, Eva Herrmann, Frank Schuppert, Hartmut Schmidt, Markus Reiser, Oliver Marschal, Martín Steffen, Michael P. Manns, Heiner Wedemeyer	2005	58
12	Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment Antiviral Therapy ·Andreas Erhardt, Katja Deterding, Yves Benhamou, Markus Reiser, Xavier Forns, Stanislas Pol, José Luís Calleja, Susanne Ross, Hans Christian Spangenberg, Javier García‐Samaniego, Michael Fuchs, Jaime Enríquez, Johannes Wiegand, Jerry O. Stern, K. Wu, George Kukolj, Martin Marquis, Pierre L. Beaulieu, Gerhard Nehmiz, Jürgen Steffgen	2009	56
13	Analysis of the Evolutionary Forces in an Immunodominant CD8 Epitope in Hepatitis C Virus at a Population Level Journal of Virology ·Christoph Neumann‐Haefelin, David N. Frick, Jing Jing Wang, Oliver G. Pybus, Shadi Salloum, Gagandeep Narula, Anna Eckart, Andrea Biezynski, Thomas Eiermann, Paul Klenerman, Sergei Viazov, Michael Roggendorf, Robert Thimme, Markus Reiser, Jörg Timm	2008	51
14	Colonic cancer and polyps Best Practice & Research Clinical Gastroenterology ·Karsten Schulmann, Markus Reiser, Wolff Schmiegel	2002	40
15	Short- to medium-term results of single-anastomosis duodeno-ileal bypass compared with one-anastomosis gastric bypass for weight recidivism after laparoscopic sleeve gastrectomy Surgery for Obesity and Related Diseases ·Marlon de la Cruz, M Büsing, Radostina Dukovska, Antonio J. Torres, Markus Reiser	2020	37
16	Degree of cross-genotype reactivity of hepatitis C virus–specific CD8+ T cells directed against NS3 # Hepatology ·Silvia Giugliano, Filiz Öezkan, Mathias Bedrejowski, Markus Kudla, Markus Reiser, Sergei Viazov, Norbert Scherbaum, Michael Roggendorf, Jörg Timm	2009	28
17	136 Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, non-genotype 1 Hepatology ·Markus Reiser, Holger Hinrichsen, Y. Benhamou, Roel Sentjens, Heiner Wedemeyer, Lucı́a Calleja, Xavier Forns, J CROENLEIN, Lip Yong Chung, Gerhard Nehmiz	2003	28
18	Viral Kinetics in Patients with Chronic Hepatitis C Treated with the Serine Protease Inhibitor Biln 2061 Antiviral Therapy ·Eva Herrmann, Stefan Zeuzem, Christoph Sarrazin, Holger Hinrichsen, Yves Benhamou, Michael P. Manns, Markus Reiser, H. W. Reesink, José Luís Calleja, Xavier Forns, Gerhard Steinmann, Gerhard Nehmiz	2006	22
19	Serine protease inhibitors as anti-hepatitis C virus agents Expert Review of Anti-infective Therapy ·Markus Reiser, Jörg Timm	2009	16
20	ß-catenin, Cox-2 and p53 immunostaining in colorectal adenomas to predict recurrence after endoscopic polypectomy International Journal of Colorectal Disease ·L. Brand, Johanna Münding, Christian Pox, Wibke Ziebarth, Markus Reiser, D Hüppe, Wolff Schmiegel, Anke Reinacher‐Schick, Andrea Tannapfel	2013	15

About Markus Reiser

Markus Reiser is a scholar working on Hepatology, Epidemiology, Virology, Oncology and Pathology and Forensic Medicine, having authored 45 papers that have together received 1.9k indexed citations. Recurring topics across this work include Hepatitis C virus research (20 papers), Liver Disease Diagnosis and Treatment (11 papers), Hepatitis B Virus Studies (9 papers), Genetic factors in colorectal cancer (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Colorectal Cancer Screening and Detection (4 papers) and Gastric Cancer Management and Outcomes (4 papers). The work is most often cited by research in Hepatology (1.2k citations), Virology (155 citations), Gastroenterology (145 citations), Epidemiology (880 citations) and Immunology (291 citations). Markus Reiser has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Wolff Schmiegel, Georg M. Lauer, Paul Klenerman, Heiner Wedemeyer, Gerhard Nehmiz, Michaela Lucas, Kei Ouchi, Raymond T. Chung, Cheryl L. Day and Arthur Y. Kim. Their work appears in journals such as Hepatology, Journal of Virology, Gastroenterology, Journal of Hepatology and RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact